Literature DB >> 11760147

Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.

M P Fox-Geiman1, S G Fisher, K Kiley, D Fletcher-Gonzalez, N Porter, P Stiff.   

Abstract

The optimal management of transplantation preparative regimen-induced nausea and vomiting remains unknown. We conducted a Phase III double-blind study to determine the efficacy and costs of oral ondansetron versus oral granisetron versus IV ondansetron and PRN rescue antiemetics for the prevention/control of nausea and vomiting associated with high-dose chemotherapy or chemoradiotherapy prior to stem cell transplantation. One hundred two patients were randomized to receive either 8 mg PO ondansetron every 8 hours, 1 mg PO granisetron every 12 hours, or 32 mg IV ondansetron every 24 hours plus 10 mg IV dexamethasone daily during and 1 day after the various preparative regimens. Study arms were compared in terms of emetic episodes, subjective nausea, amount and cost of rescue antiemetics used, and total costs. Response was defined as complete response (CR), no emesis with no or mild nausea and no rescue antiemetics; major response (MR), 1 episode of emesis or moderate nausea with or without rescue antiemetics; and major efficacy (ME), CR + MR. Subjective nausea was assessed using a 100-mm visual analog scale (VAS) with 0 = no nausea. Ninety-six patients completed the study; the trial was analyzed according to intention-to-treat. Overall CR rates were: 48% for oral ondansetron, 47% for oral granisetron, and 49% for IV ondansetron. Overall ME rates were 82% for oral ondansetron, 84% for oral granisetron, and 81% for IV ondansetron. Mean VAS scores were 32 for oral ondansetron, 32 for oral granisetron, and 27 for IV ondansetron. None of the differences were statistically significant. A cost analysis revealed significant differences among all arms (P = .0001, all comparisons). All 3 regimens had similar efficacy in this BMT population; oral ondansetron was the most cost-effective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11760147     DOI: 10.1053/bbmt.2001.v7.pm11760147

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

1.  PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.

Authors:  Rachel Huddart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-06       Impact factor: 2.089

2.  Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.

Authors:  Su-Peng Yeh; Woei-Chung Lo; Ching-Yun Hsieh; Li-Yuan Bai; Ching-Chan Lin; Po-Han Lin; Chen-Yuan Lin; Yu-Min Liao; Chang-Fang Chiu
Journal:  Support Care Cancer       Date:  2013-12-07       Impact factor: 3.603

Review 3.  Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.

Authors:  Vanessa Piechotta; Anne Adams; Madhuri Haque; Benjamin Scheckel; Nina Kreuzberger; Ina Monsef; Karin Jordan; Kathrin Kuhr; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2021-11-16

Review 4.  The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.

Authors:  Michael S Broder; Claudio Faria; Annette Powers; Jehangeer Sunderji; Dasha Cherepanov
Journal:  Am Health Drug Benefits       Date:  2014-05

5.  Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.

Authors:  Maurizio Musso; Renato Scalone; Vincenza Bonanno; Alessandra Crescimanno; Vita Polizzi; Ferdinando Porretto; Carlo Bianchini; Tania Perrone
Journal:  Support Care Cancer       Date:  2008-10-07       Impact factor: 3.603

6.  A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.

Authors:  Joseph M Brandwein; Jack T Seki; Eshetu G Atenafu; Amr Rostom; Andrzej Lutynski; Anna Rydlewski; Aaron D Schimmer; Andre C Schuh; Vikas Gupta; Karen W L Yee
Journal:  Support Care Cancer       Date:  2018-10-19       Impact factor: 3.603

7.  Antiemetic Prophylaxis with Fosaprepitant and 5-HT3-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Karin Melanie Cabanillas Stanchi; Semjon Willier; Julia Vek; Patrick Schlegel; Manon Queudeville; Nora Rieflin; Veronika Klaus; Melanie Gansel; Joachim Vincent Rupprecht; Tim Flaadt; Vera Binder; Tobias Feuchtinger; Peter Lang; Rupert Handgretinger; Michaela Döring
Journal:  Drug Des Devel Ther       Date:  2020-09-25       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.